These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 29246893)

  • 1. Lid splinting eyelid retraction technique: a minimised sterile approach for intravitreal injections.
    Munro M; Williams GR; Ells A; Fielden M; Kherani A; Mitchell P; Ruzicki J; Adatia FA
    Br J Ophthalmol; 2018 Sep; 102(9):1254-1258. PubMed ID: 29246893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bimanual assisted eyelid retraction technique for intravitreal injections.
    Fineman MS; Hsu J; Spirn MJ; Kaiser RS
    Retina; 2013 Oct; 33(9):1968-70. PubMed ID: 23609121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
    Shah CP; Garg SJ; Vander JF; Brown GC; Kaiser RS; Haller JA;
    Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Endophthalmitis after Intravitreal Injection: A Multivariable Analysis Based on Injection Protocol and Povidone Iodine Strength.
    Stem MS; Rao P; Lee IJ; Woodward MA; Faia LJ; Wolfe JD; Capone A; Covert D; Dass AB; Drenser KA; Garretson BR; Hassan TS; Margherio A; Oh KT; Raephaelian PV; Randhawa S; Sneed S; Trese MT; Yedavally S; Williams GA; Ruby AJ
    Ophthalmol Retina; 2019 Jan; 3(1):3-7. PubMed ID: 30929813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT).
    Meredith TA; McCannel CA; Barr C; Doft BH; Peskin E; Maguire MG; Martin DF; Prenner JL;
    Ophthalmology; 2015 Apr; 122(4):817-21. PubMed ID: 25600198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor: Experience in Saudi Arabia.
    Al-Rashaed S; Alsulaiman SM; Alrushood AA; Almasaud J; Arevalo JF
    Middle East Afr J Ophthalmol; 2016; 23(1):60-3. PubMed ID: 26957840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask.
    Shimada H; Hattori T; Mori R; Nakashizuka H; Fujita K; Yuzawa M
    Graefes Arch Clin Exp Ophthalmol; 2013 Aug; 251(8):1885-90. PubMed ID: 23389553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endophthalmitis following intravitreal injection of anti-vascular endothelial growth factor agents.
    Storey PP; Patel D; Garg S
    Can J Ophthalmol; 2020 Aug; 55(4):286-292. PubMed ID: 32204888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LOW ENDOPHTHALMITIS RATES AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS IN AN OPERATION ROOM: A Retrospective Multicenter Study.
    Freiberg FJ; Brynskov T; Munk MR; Sørensen TL; Wolf S; Wirth MA; Becker M; Michels S
    Retina; 2017 Dec; 37(12):2341-2346. PubMed ID: 28099318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COMPARATIVE RISK OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH BEVACIZUMAB, AFLIBERCEPT, AND RANIBIZUMAB.
    Bavinger JC; Yu Y; VanderBeek BL
    Retina; 2019 Oct; 39(10):2004-2011. PubMed ID: 30312260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting.
    Pilli S; Kotsolis A; Spaide RF; Slakter J; Freund KB; Sorenson J; Klancnik J; Cooney M
    Am J Ophthalmol; 2008 May; 145(5):879-82. PubMed ID: 18329624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials.
    Bhavsar AR; Googe JM; Stockdale CR; Bressler NM; Brucker AJ; Elman MJ; Glassman AR;
    Arch Ophthalmol; 2009 Dec; 127(12):1581-3. PubMed ID: 20008710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LONG-TERM VISUAL OUTCOMES AND CLINICAL FEATURES AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTION-RELATED ENDOPHTHALMITIS.
    Rayess N; Obeid A; Storey PP; Juliano J; Rahimy E; Moshfeghi AA; Garg S; Hsu J
    Retina; 2019 Nov; 39(11):2070-2076. PubMed ID: 30157114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
    Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
    Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.
    Inoue M; Kobayakawa S; Sotozono C; Komori H; Tanaka K; Suda Y; Matsushima H; Kinoshita S; Senoo T; Tochikubo T; Kadonosono K
    Ophthalmologica; 2011; 226(3):145-50. PubMed ID: 21811052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept.
    Forooghian F; Albiani DA; Kirker AW; Merkur AB
    Can J Ophthalmol; 2017 Dec; 52(6):616-619. PubMed ID: 29217032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endophthalmitis after Anti-VEGF Intravitreal Injections with Aqueous Chlorhexidine versus Povidone-Iodine as Ocular Antiseptics.
    Ton NS; Goncharov V; Zapata I; Adam MK
    Ophthalmol Retina; 2024 Jun; 8(6):521-526. PubMed ID: 38122867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of Prefilled Syringes on Endophthalmitis Following Intravitreal Injection of Ranibizumab.
    Storey PP; Tauqeer Z; Yonekawa Y; Todorich B; Wolfe JD; Shah SP; Shah AR; Koto T; Abbey AM; Morizane Y; Sharma P; Wood EH; Morizane-Hosokawa M; Pendri P; Pancholy M; Harkey S; Jeng-Miller KW; Obeid A; Borkar DS; Chen E; Williams P; Okada AA; Inoue M; Shiraga F; Hirakata A; Shah CP; Prenner J; Garg S;
    Am J Ophthalmol; 2019 Mar; 199():200-208. PubMed ID: 30552891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of endophthalmitis after intravitreal injection of antivascular endothelial growth factor medications using topical lidocaine gel anesthesia.
    Inman ZD; Anderson NG
    Retina; 2011 Apr; 31(4):669-72. PubMed ID: 21178659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates.
    Englander M; Chen TC; Paschalis EI; Miller JW; Kim IK
    Br J Ophthalmol; 2013 Apr; 97(4):460-5. PubMed ID: 23390167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.